crizanlizumab (Adakveo) Report issue

Biologics mAb Orphan Drug FDA Approved FDA First in Class
AACT

Active Ingredient History

NOW
  • Now
Crizanlizumab, sold under the brand name Adakveo among others, is a monoclonal antibody medication that binds to P-selectin. It is a medication used to reduce the frequency of vaso-occlusive crisis in people aged 16 years and older who have sickle cell anemia. It is given by injection into a vein.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$176.4250 - $233.3450
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

selg1

Organizations (9)

Research & Development (9)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Anemia, Sickle Cell (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Anemia, Sickle Cell (Phase 4)

COVID-19 (Phase 2)

Glioblastoma (Phase 2)

Livedoid Vasculopathy (Phase 2)

Priapism (Phase 2)

Primary Myelofibrosis (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial Organizations: 9

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue